Compare MQ & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | HRMY |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2021 | 2020 |
| Metric | MQ | HRMY |
|---|---|---|
| Price | $15.96 | $38.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $5.36 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.2M | 890.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | $624,884,000.00 | ★ $868,453,000.00 |
| Revenue This Year | $16.89 | $19.75 |
| Revenue Next Year | $16.36 | $12.88 |
| P/E Ratio | ★ N/A | $21.06 |
| Revenue Growth | ★ 23.25 | 21.51 |
| 52 Week Low | $3.70 | $25.52 |
| 52 Week High | $18.69 | $40.87 |
| Indicator | MQ | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 63.35 |
| Support Level | $16.52 | $37.12 |
| Resistance Level | $17.79 | $39.07 |
| Average True Range (ATR) | 0.72 | 1.60 |
| MACD | -0.53 | 0.28 |
| Stochastic Oscillator | 14.16 | 82.13 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.